| Title |
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
|
|---|---|
| Published in |
Current Treatment Options in Oncology, August 2018
|
| DOI | 10.1007/s11864-018-0562-9 |
| Pubmed ID | |
| Authors |
Beatriz Wills, Julie R. Brahmer, Jarushka Naidoo |
| Abstract |
Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospective clinical trial exists to guide recommendations for optimal and more specific immunosuppressive treatments rather than corticosteroids, further studies may lead to a more mechanistic-based approach towards these toxicities in the future. In relation to current practice, we recommend adherence to the recent published guidelines which emphasize the importance of early recognition and administration of temporary immunosuppressive therapy with corticosteroids in most cases, depending on the organ system involved, and the severity of toxicity. Recognition of these toxicities is increasingly important as the use of these agents expand within different indications for patients with lung cancers, and to other tumor types. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 16% |
| Researcher | 8 | 14% |
| Student > Master | 6 | 11% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 3 | 5% |
| Other | 9 | 16% |
| Unknown | 17 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Neuroscience | 2 | 4% |
| Social Sciences | 2 | 4% |
| Other | 3 | 5% |
| Unknown | 19 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2020.
All research outputs
#7,326,749
of 23,099,576 outputs
Outputs from Current Treatment Options in Oncology
#177
of 677 outputs
Outputs of similar age
#125,621
of 330,840 outputs
Outputs of similar age from Current Treatment Options in Oncology
#2
of 9 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 677 research outputs from this source. They receive a mean Attention Score of 3.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.